Pluvicto improves survival in metastatic hormone-sensitive prostate cancer across patient subgroups.

Novartis announced that Pluvicto combined with standard care significantly improves radiographic progression-free survival (rPFS) in metastatic hormone-sensitive prostate cancer (mHSPC) patients, regardless of disease volume or presentation. The PSMAddition trial showed a 28% reduction in risk of progression or death, supporting early treatment use. Safety profiles were consistent, with manageable side effects. Novartis is also advancing actinium-based radioligand therapy with promising Phase 1 data and ongoing Phase 3 trials, aiming to expand treatment options for prostate cancer patients globally.